#AAD24 roundup: Da­ta from Sanofi, Alu­mis, Gal­der­ma and more

Be­low are no­table up­dates from the Amer­i­can Acad­e­my of Der­ma­tol­ogy’s an­nu­al meet­ing over the week­end:

Sanofi amends tri­al pro­to­col

Sanofi has big plans for am­lite­limab, the mon­o­clon­al an­ti­body that binds to OX40-Lig­and ac­quired in the $1.5 bil­lion Kymab bolt-on from 2021. But first up is atopic der­mati­tis.

Ad­di­tion­al Phase IIb da­ta will prompt Sanofi to change its Phase III tri­al pro­to­col to al­low for in­creased time off drug, mov­ing to 40 weeks out from 28 weeks, glob­al head of im­munol­o­gy Sha­ju Backer told End­points News. Pa­tients with high re­sponse rates from an ear­li­er part of the study who con­tin­ued tak­ing the drug al­so main­tained their treat­ment lev­els out to 28 weeks, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER